Novo Nordisk India has announced a major price reduction for all strengths of Wegovy®, aiming to make this obesity treatment more accessible to a wider population living with overweight and obesity in the country. With the revised pricing, the starting dose of 0.25 mg will now be available at an effective weekly cost of Rs 2,712, offering substantial financial relief for patients initiating therapy.
Wegovy® was introduced across India in June 2025 as a once-weekly treatment delivered through the FlexTouch® device. Available in five strengths—0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg—it remains the only approved therapy in India indicated for both chronic weight management and reduction of cardiovascular risk in individuals with overweight or obesity. Clinical data show that up to one in three patients can achieve at least 20% weight loss when the medication is paired with lifestyle modifications, addressing a significant unmet need in obesity management.
This price revision reflects Novo Nordisk India’s commitment to expanding treatment access and supporting people living with obesity across the country. Since the product’s launch, the company has worked to understand patient and clinician needs and improve affordability while maintaining high standards of quality and safety. The rising burden of obesity in India makes such measures critical for improving long-term health outcomes.
Wegovy® continues to be offered through its FlexTouch® delivery device in all five dose strengths, allowing for gradual dose escalation and personalized treatment plans suited to long-term weight management.
Also Read
